FDA rejects Zealand Pharma's GLP-2 analog in rare bowel disease

[cafead]

via The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing a lack of evidence.

article source